The impact of the TailorX and RxPonder studies and the use of Oncotype Dx in clinical practice: A single Breast Cancer Center experience

被引：0
|
作者：
Nasikas, D. [1 ]
Fostira, F. [2 ]
Tsoulos, N. [3 ]
Fokianou, A. [1 ]
Kontogianni, P. [1 ]
Ntasiou, P. [1 ]
Xepapadakis, G. [1 ]
机构：
[1] IASO Hosp, Breast Clin 2, Athens, Greece
[2] NCSR DEMOCRITOS, Mol Diagnost Lab, Athens, Greece
[3] Genekor Med SA, Athens, Greece
来源：
BREAST | 2023年 / 68卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P152
引用
收藏
页码：S75 / S75
页数：1
相关论文
共 50 条
  • [31] Oncotype DX recurrence score in node-positive patients in the post-RxPONDER era: a single-institution experience
    Han, Rachel
    Brogi, Edi
    Thompson, Donna
    El-Tamer, Mahmoud
    Morrow, Monica
    Wen, Hannah Y.
    BREAST CANCER RESEARCH AND TREATMENT, 2025, : 449 - 454
  • [32] Impact of Oncotype DX Recurrence Score in the Management of Breast Cancer Cases
    Nguyen, Michaela T.
    Stessin, Alexander
    Nagar, Himanshu
    D'Alfonso, Timothy M.
    Chen, Zhengming
    Cigler, Tessa
    Hayes, Mary Kay
    Shin, Sandra J.
    CLINICAL BREAST CANCER, 2014, 14 (03) : 182 - 190
  • [33] The Oncotype DX® assay use in breast cancer in an Australian institutional setting
    Choi, J. D. W.
    Hughes, T. M. D.
    Marx, G.
    Boyages, J.
    Rutovitz, J.
    Hasovits, C.
    Parasyn, A.
    Edirimanne, S.
    Ngui, N. K.
    BREAST, 2021, 56 : S66 - S67
  • [34] BUDGET IMPACT ANALYSIS OF THE ONCOTYPE DX® BREAST CANCER TEST IN FRANCE
    Rouzier, R.
    Laas, E.
    Chereau, E.
    Gligorov, J.
    BREAST, 2013, 22 : S87 - S88
  • [35] Oncotype Dx assay impact on decision making chemotherapy in breast cancer
    Muhibullah, N.
    Khout, H.
    Whisker, L.
    Gutteridge, E.
    BRITISH JOURNAL OF SURGERY, 2017, 104 : 29 - 29
  • [36] Oncotype DX testing in early-stage node-positive breast cancer and impact on chemotherapy use at a comprehensive cancer center.
    Losk, Katya
    Freedman, Rachel A.
    Mittendorf, Elizabeth A.
    Tan-Wasielewski, Zhenying
    Trippa, Lorenzo
    King, Tari A.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [37] Cost-Effectiveness Evaluation of the Oncotype DX® Breast Cancer Assay in Clinical Practice in the UK.
    Holt, S. D. H.
    Bennett, H.
    Bertelli, G.
    Valentine, W. J.
    Phillips, C. J.
    CANCER RESEARCH, 2011, 71
  • [38] Appropriate use of Oncotype DX in breast cancer patients: An NCDB analysis
    Govert, Kristen
    Voci, Amy
    Walsh, Kendall
    Boselli, Danielle
    Hadzikadic-Gusic, Lejla
    Forster, Meghan
    Sarma, Deba
    Sarantou, Terry
    White, Richard, Jr.
    ANNALS OF SURGICAL ONCOLOGY, 2017, 24 : 177 - 178
  • [39] Oncotype DX testing in node-positive breast cancer strongly impacts chemotherapy use at a comprehensive cancer center
    Katya Losk
    Rachel A. Freedman
    Alison Laws
    Olga Kantor
    Elizabeth A. Mittendorf
    Zhenying Tan-Wasielewski
    Lorenzo Trippa
    Nancy U. Lin
    Eric P. Winer
    Tari A. King
    Breast Cancer Research and Treatment, 2021, 185 : 215 - 227
  • [40] Oncotype DX testing in node-positive breast cancer strongly impacts chemotherapy use at a comprehensive cancer center
    Losk, Katya
    Freedman, Rachel A.
    Laws, Alison
    Kantor, Olga
    Mittendorf, Elizabeth A.
    Tan-Wasielewski, Zhenying
    Trippa, Lorenzo
    Lin, Nancy U.
    Winer, Eric P.
    King, Tari A.
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 185 (01) : 215 - 227
12345